MX2020014205A - Uso de cromatografia de interaccion hidrofobica multiple para preparar un polipeptido a partir de una mezcla. - Google Patents

Uso de cromatografia de interaccion hidrofobica multiple para preparar un polipeptido a partir de una mezcla.

Info

Publication number
MX2020014205A
MX2020014205A MX2020014205A MX2020014205A MX2020014205A MX 2020014205 A MX2020014205 A MX 2020014205A MX 2020014205 A MX2020014205 A MX 2020014205A MX 2020014205 A MX2020014205 A MX 2020014205A MX 2020014205 A MX2020014205 A MX 2020014205A
Authority
MX
Mexico
Prior art keywords
mixture
hydrophobic interaction
polypeptide
interaction chromatography
preparing
Prior art date
Application number
MX2020014205A
Other languages
English (en)
Inventor
Stefanie Mcdermott
John Mattila
Isabelle Livigni
James Reilly
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020014205A publication Critical patent/MX2020014205A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/30—Partition chromatography
    • B01D15/305—Hydrophilic interaction chromatography [HILIC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

Las modalidades de la presente descripción son dirigidas a métodos para preparar un polipéptido objetivo a partir de una mezcla que incluye el polipéptido objetivo. El método puede incluir poner en contacto la mezcla en un aparato de cromatografía de interacción hidrofóbica (HIC) que incluye múltiples zonas cromatográficas. El método puede incluir además hacer pasar el polipéptido objetivo a través de las salidas de al menos una primera zona y una segunda zona del aparato de HIC. Un tiempo de residencia para la mezcla que incluye el polipéptido objetivo en una primera zona puede ser aproximadamente el mismo que el tiempo de residencia de una o más fases móviles en la segunda zona.
MX2020014205A 2018-07-02 2019-07-01 Uso de cromatografia de interaccion hidrofobica multiple para preparar un polipeptido a partir de una mezcla. MX2020014205A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862693024P 2018-07-02 2018-07-02
PCT/US2019/040148 WO2020010004A1 (en) 2018-07-02 2019-07-01 Use of multiple hydrophobic interaction chromatography for preparing a polypeptide from a mixture

Publications (1)

Publication Number Publication Date
MX2020014205A true MX2020014205A (es) 2021-05-27

Family

ID=67587924

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014205A MX2020014205A (es) 2018-07-02 2019-07-01 Uso de cromatografia de interaccion hidrofobica multiple para preparar un polipeptido a partir de una mezcla.

Country Status (14)

Country Link
US (1) US11884698B2 (es)
EP (1) EP3818069A1 (es)
JP (1) JP2021529749A (es)
KR (1) KR20210027296A (es)
CN (1) CN112638931A (es)
AU (1) AU2019299321A1 (es)
BR (1) BR112020025624A2 (es)
CA (1) CA3103817A1 (es)
EA (1) EA202190163A1 (es)
IL (1) IL279564A (es)
MX (1) MX2020014205A (es)
SG (1) SG11202012265SA (es)
TW (1) TW202005694A (es)
WO (1) WO2020010004A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641050A (zh) 2016-08-16 2019-04-16 里珍纳龙药品有限公司 用于对混合物中的个体抗体进行量化的方法
CN109923411B (zh) 2016-10-25 2022-05-31 里珍纳龙药品有限公司 用于色谱数据分析的方法和系统
WO2022234412A1 (en) 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937188A (en) 1986-04-15 1990-06-26 Northeastern University Enzyme activity amplification method for increasing assay sensitivity
US4801726A (en) 1986-04-15 1989-01-31 Northeastern University Repetitive hit-and-run immunoassay and stable support-analyte conjugates; applied to T-2 toxin
US5190864A (en) 1986-04-15 1993-03-02 Northeastern University Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material
US5412083A (en) 1992-04-16 1995-05-02 Northeastern University Carbohydrate heterobifunctional cross-linking reagent
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AU4986596A (en) 1995-02-16 1996-09-04 Massachusetts Health Research Institute, Inc. Purified tetanus toxoid and toxin
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0964057B1 (en) 1998-05-11 2004-12-22 Tosoh Corporation Method for separating nucleic acids by means of liquid chromatography
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
DK1324776T4 (en) 2000-10-12 2018-05-28 Genentech Inc CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
US7101982B2 (en) 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
WO2004020971A2 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
CA2498725C (en) 2002-09-13 2014-07-08 Biogen Idec Inc. Method of purifying polypeptides by simulated moving bed chromatography
EP1614693A4 (en) 2003-03-31 2006-07-19 Kirin Brewery PURIFICATION OF A HUMAN MONOCLONAL ANTIBODY AND A HUMAN POLYCLONAL ANTIBODY
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
ATE462716T1 (de) 2003-10-24 2010-04-15 Amgen Inc Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
NZ548126A (en) 2004-02-27 2009-10-30 Ge Healthcare Bio Sciences Ab A process for the purification of antibodies involving addition of a second resin
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
WO2006020622A1 (en) 2004-08-09 2006-02-23 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
US7795405B2 (en) 2004-08-09 2010-09-14 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
PL1827691T3 (pl) 2004-10-21 2017-07-31 Ge Healthcare Bioprocess R&D Ab Matryca chromatograficzna
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
EP1775001A1 (en) 2005-10-13 2007-04-18 Xendo Holding B.V. Device for chromatographic separations
WO2007064281A1 (en) 2005-12-02 2007-06-07 Ge Healthcare Bio-Sciences Ab Hydrophobic interaction chromatography
CN101410137A (zh) 2006-03-28 2009-04-15 霍夫曼-拉罗奇有限公司 抗-igf-1r人单克隆抗体制剂
EP2004689A4 (en) 2006-04-05 2010-06-02 Abbott Biotech Ltd PURIFICATION OF ANTIBODIES
JP5216002B2 (ja) 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
US9766217B2 (en) 2006-09-08 2017-09-19 Novo Nordisk A/S Methods of optimizing chromatographic separation of polypeptides
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
WO2008109721A1 (en) 2007-03-06 2008-09-12 Introgen Therapeutics, Inc. Chromatographic methods for assessing adenovirus purity
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
CN101687119B (zh) 2007-06-15 2013-06-12 通用电气健康护理生物科学股份公司 色谱方法
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
WO2009094203A2 (en) 2008-01-25 2009-07-30 Biogen Idec Ma Inc. Automated system and method for monitoring chromatography column performance, and applications thereof
CA2734246C (en) 2008-08-15 2021-04-27 Biogen Idec Ma Inc. Methods for evaluating chromatography column performance
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
SG175188A1 (en) 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CA3077531C (en) 2009-06-16 2022-09-20 Genzyme Corporation Improved methods for purification of recombinant aav vectors
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
EP2491055A2 (en) 2009-10-20 2012-08-29 Abbott Laboratories Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
US8246833B2 (en) 2009-12-17 2012-08-21 Ge Healthcare Bio-Sciences Ab Chromatography column and maintenance method
MX2012009283A (es) 2010-02-12 2012-09-07 Dsm Ip Assets Bv Purificacion de anticuerpo de una unidad.
WO2012030512A1 (en) * 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
MX2013003182A (es) * 2010-09-20 2013-04-24 Abbvie Inc Purificacion de anticuerpos por cromatografia de lecho movil simulada.
PL2637690T3 (pl) 2010-11-11 2017-03-31 Abbvie Biotechnology Ltd Płynne formulacje zawierające przeciwciało anty-tnf alfa o wysokim stężeniu
EP2652491B1 (en) 2010-12-15 2017-11-29 Baxalta GmbH Eluate collection using conductivity gradient
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
EP2773439A4 (en) 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR DECOMPOSING HETEROGENEOUS ANTIBODY AGGREGATES
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
AU2012340826A1 (en) 2011-11-21 2014-05-29 Genentech, Inc. Purification of anti-c-met antibodies
PT2791176T (pt) 2011-12-15 2018-11-05 Prestige Biopharma Pte Ltd Um método de purificação de anticorpos
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
EP2656892A1 (en) * 2012-04-23 2013-10-30 Merck Patent GmbH Chromatography method
WO2013177118A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of non-human antibodies using protein a affinity chromatography
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2014025771A2 (en) 2012-08-06 2014-02-13 Biogen Idec Ma Inc. Methods and compositions for inactivating enveloped viruses
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
EP2934588A4 (en) 2012-12-20 2016-09-28 Medimmune Llc LIQUID ANTIBODY FORMULATION HAVING ENHANCED AGGREGATION PROPERTIES
RU2768003C2 (ru) 2013-03-08 2022-03-22 Джензим Корпорейшн Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2926301A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
TWI670279B (zh) 2013-03-15 2019-09-01 美商艾爾德生物製藥股份有限公司 抗體純化及純度監測
JP6592426B2 (ja) 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR101569783B1 (ko) 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
US9150938B2 (en) 2013-06-12 2015-10-06 Orochem Technologies, Inc. Tagatose production from deproteinized whey and purification by continuous chromatography
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
KR20160050062A (ko) 2013-09-05 2016-05-10 제넨테크, 인크. 크로마토그래피 재사용 방법
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20160251441A1 (en) 2013-10-25 2016-09-01 Medimmune, Llc Antibody purification
US10115576B2 (en) 2013-12-12 2018-10-30 Waters Technologies Corporation Method and an apparatus for analyzing a complex sample
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
FR3025515B1 (fr) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
AU2015355150A1 (en) 2014-12-02 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods for treating dry eye disease by administering an IL-6R antagonist
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
CN108602889A (zh) 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
CA3009161A1 (en) 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
GB201602938D0 (en) 2016-02-19 2016-04-06 Ucb Biopharma Sprl Protein purification
CA3027288A1 (en) 2016-06-14 2017-12-21 Biogen Ma Inc. Hydrophobic interaction chromatography for purification of oligonucleotides
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
EP3500586B1 (en) * 2016-10-17 2021-02-24 Enzene Biosciences Ltd. Continuous process for reducing heterogeneity of therapeutic protein
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
KR20180064316A (ko) 2016-12-05 2018-06-14 한미약품 주식회사 재조합 단백질의 개선된 정제 방법
MA49962A (fr) 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
US20210010055A1 (en) 2018-03-16 2021-01-14 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
WO2019178495A1 (en) 2018-03-16 2019-09-19 Biogen Ma Inc. Methods for purifying recombinant adeno-associated viruses
WO2019191416A1 (en) 2018-03-29 2019-10-03 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies
EP3810650A1 (en) 2018-06-19 2021-04-28 Bristol-Myers Squibb Company Methods of purifying proteins using chromatography
US20220267369A1 (en) 2018-07-25 2022-08-25 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
WO2020037016A1 (en) 2018-08-15 2020-02-20 Bristol-Myers Squibb Company Protein fragmentation control strategy by re-oxidation in downstream chromatography
KR20210090649A (ko) 2018-11-05 2021-07-20 브리스톨-마이어스 스큅 컴퍼니 Peg화 단백질의 정제 방법
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
JP2022527493A (ja) 2019-03-29 2022-06-02 ブリストル－マイヤーズ スクイブ カンパニー クロマトグラフィー樹脂の疎水性を測定する方法
JP2022539148A (ja) 2019-06-28 2022-09-07 武田薬品工業株式会社 アデノ随伴ウイルスの精製方法

Also Published As

Publication number Publication date
JP2021529749A (ja) 2021-11-04
WO2020010004A1 (en) 2020-01-09
EP3818069A1 (en) 2021-05-12
IL279564A (en) 2021-01-31
US20200002373A1 (en) 2020-01-02
CN112638931A (zh) 2021-04-09
SG11202012265SA (en) 2021-01-28
AU2019299321A1 (en) 2021-01-07
TW202005694A (zh) 2020-02-01
KR20210027296A (ko) 2021-03-10
US11884698B2 (en) 2024-01-30
BR112020025624A2 (pt) 2021-03-23
CA3103817A1 (en) 2020-01-09
EA202190163A1 (ru) 2021-03-30

Similar Documents

Publication Publication Date Title
MX2020014205A (es) Uso de cromatografia de interaccion hidrofobica multiple para preparar un polipeptido a partir de una mezcla.
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
BR112017025529A2 (pt) agentes de ligação ao tigit e usos destes
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
EA201891366A1 (ru) Гуманизированные антитела против cd73
GEP20207162B (en) Lag-3-binding molecules and methods of use thereof
MX2021014286A (es) Proteinas multiespecificas.
MX2016013216A (es) Dispositivos mejorados para la separacion de materiales biologicos.
PH12019502298A1 (en) Monoclonal antibody to pd-l1
MX2020000288A (es) Cromatografia.
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
MX2016011567A (es) Sintesis de clomifeno usando un solvente unico.
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
EA201992431A1 (ru) Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
WO2018231339A3 (en) TYROSINE PHOSPHORYLATED ANTI-PD-1 ANTIBODIES AND USES THEREOF
BR112018005464A2 (pt) expressão de proteínas contendo fc
EP3885763A4 (en) ANALYSIS APPARATUS HAVING A PLURALITY OF LIQUID CHROMATOGRAPHS, AND ANALYSIS METHOD THEREOF